ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Microprotein MP104 Promotes Malignant Progression of Colorectal Cancer Through Regulating Protein Translation.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Colorectal cancer (CRC) remains a major cause of cancer mortality, necessitating the identification of novel oncogenic drivers. We report the discovery of MP104, a 104-amino acid microprotein encoded by the long non-coding RNA ZEB1-AS1, which is endogenously expressed and upregulated in CRC with strong association to poor prognosis. Functional assays revealed that MP104 promotes CRC cell proliferation, migration, invasion, and metastasis. Mechanistically, MP104 interacts with UBE2O to facilitate AMPKα2 ubiquitination and degradation, thereby activating mTOR signaling. This activation enhances EIF4B phosphorylation and stability, while MP104 further inhibits RNF40-mediated EIF4B ubiquitination, collectively sustaining translational upregulation. Thus, MP104 drives CRC progression primarily through reprogramming protein translation via the UBE2O-AMPKα2-mTOR-EIF4B axis, establishing it as a key regulator of oncogenic translational control and a promising biomarker and therapeutic target in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.